Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Current Leases (2021 - 2025)

Avidity Biosciences' Current Leases history spans 5 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Current Leases rose 2.45% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, up 2.45%, while the annual FY2025 figure was $3.9 million, 2.45% up from the prior year.
  • Current Leases reached $3.9 million in Q4 2025 per RNA's latest filing, down from $4.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $4.0 million in Q3 2025 to a low of $1.8 million in Q4 2021.
  • Average Current Leases over 5 years is $3.4 million, with a median of $3.6 million recorded in 2023.
  • Peak YoY movement for Current Leases: skyrocketed 75.52% in 2022, then grew 2.45% in 2025.
  • A 5-year view of Current Leases shows it stood at $1.8 million in 2021, then surged by 75.52% to $3.1 million in 2022, then rose by 17.2% to $3.6 million in 2023, then rose by 5.63% to $3.8 million in 2024, then increased by 2.45% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Current Leases are $3.9 million (Q4 2025), $4.0 million (Q3 2025), and $3.9 million (Q2 2025).